1. Home
  2. CRBP vs THRY Comparison

CRBP vs THRY Comparison

Compare CRBP & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.42

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

N/A

Current Price

$1.42

Market Cap

179.6M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
THRY
Founded
2009
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
179.6M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
CRBP
THRY
Price
$5.42
$1.42
Analyst Decision
Strong Buy
Hold
Analyst Count
10
4
Target Price
★ $34.03
$4.00
AVG Volume (30 Days)
★ 1.1M
647.2K
Earning Date
11-11-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.50
EPS
N/A
★ N/A
Revenue
$4,822,272.00
★ $785,015,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 97.62
N/A
52 Week Low
$5.13
$1.30
52 Week High
$20.56
$12.57

Technical Indicators

Market Signals
Indicator
CRBP
THRY
Relative Strength Index (RSI) 23.84 29.44
Support Level N/A N/A
Resistance Level $8.13 $2.17
Average True Range (ATR) 0.42 0.10
MACD -0.10 -0.00
Stochastic Oscillator 10.17 15.44

Price Performance

Historical Comparison
CRBP
THRY

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.

Share on Social Networks: